Explore
Validate
Learn
Western blot
ImmunocytochemistryAntibody data
- Antibody Data
- Antigen structure
- References [19]
- Comments [0]
- Validations
- Western blot [1]
- Immunohistochemistry [1]
- Flow cytometry [5]
Submit
Validation data
Reference
Comment
Report error
- Product number
- NBP1-97657 - Provider product page
- Provider
- Novus Biologicals
- Proper citation
- Novus Cat#NBP1-97657, RRID:AB_11162489
- Product name
- Mouse Monoclonal LAG-3 Antibody
- Antibody type
- Monoclonal
- Description
- Protein A or G purified. Recognizes the 30 aa extra-loop of the first N-terminal D1 domain of human LAG-3.
- Reactivity
- Human
- Host
- Mouse
- Isotype
- IgG
- Vial size
- 50 ug
- Concentration
- 1.0 mg/ml
- Storage
- Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
Submitted references CTLA-4 and PD-1 dual blockade induces SIV reactivation without control of rebound after antiretroviral therapy interruption.
Profiling Immune Escape in Hodgkin's and Diffuse large B-Cell Lymphomas Using the Transcriptome and Immunostaining.
LAG-3 Represents a Marker of CD4+ T Cells with Regulatory Activity in Patients with Bone Fracture.
Function and regulation of LAG3 on CD4+CD25- T cells in non-small cell lung cancer.
TIM-3 Engagement Promotes Effector Memory T Cell Differentiation of Human Antigen-Specific CD8 T Cells by Activating mTORC1.
Human lymphocyte activation gene-3 molecules expressed by activated T cells deliver costimulation signal for dendritic cell activation.
Human lymphocyte activation gene-3 molecules expressed by activated T cells deliver costimulation signal for dendritic cell activation.
A soluble lymphocyte activation gene-3 (sLAG-3) protein as a prognostic factor in human breast cancer expressing estrogen or progesterone receptors.
The negative regulatory function of the lymphocyte-activation gene-3 co-receptor (CD223) on human T cells.
Immunological mechanisms elicited at the tumour site by lymphocyte activation gene-3 (LAG-3) versus IL-12: sharing a common Th1 anti-tumour immune pathway.
T Lymphocytes infiltrating various tumour types express the MHC class II ligand lymphocyte activation gene-3 (LAG-3): role of LAG-3/MHC class II interactions in cell-cell contacts.
T Lymphocytes infiltrating various tumour types express the MHC class II ligand lymphocyte activation gene-3 (LAG-3): role of LAG-3/MHC class II interactions in cell-cell contacts.
CD3/TCR complex-associated lymphocyte activation gene-3 molecules inhibit CD3/TCR signaling.
Characterization of the major histocompatibility complex class II binding site on LAG-3 protein.
Characterization of the major histocompatibility complex class II binding site on LAG-3 protein.
Cellular expression and tissue distribution of the human LAG-3-encoded protein, an MHC class II ligand.
Cellular expression and tissue distribution of the human LAG-3-encoded protein, an MHC class II ligand.
Characterization of the lymphocyte activation gene 3-encoded protein. A new ligand for human leukocyte antigen class II antigens.
Characterization of the lymphocyte activation gene 3-encoded protein. A new ligand for human leukocyte antigen class II antigens.
Harper J, Gordon S, Chan CN, Wang H, Lindemuth E, Galardi C, Falcinelli SD, Raines SLM, Read JL, Nguyen K, McGary CS, Nekorchuk M, Busman-Sahay K, Schawalder J, King C, Pino M, Micci L, Cervasi B, Jean S, Sanderson A, Johns B, Koblansky AA, Amrine-Madsen H, Lifson J, Margolis DM, Silvestri G, Bar KJ, Favre D, Estes JD, Paiardini M
Nature medicine 2020 Apr;26(4):519-528
Nature medicine 2020 Apr;26(4):519-528
Profiling Immune Escape in Hodgkin's and Diffuse large B-Cell Lymphomas Using the Transcriptome and Immunostaining.
Péricart S, Tosolini M, Gravelle P, Rossi C, Traverse-Glehen A, Amara N, Franchet C, Martin E, Bezombes C, Laurent G, Brousset P, Fournié JJ, Laurent C
Cancers 2018 Oct 31;10(11)
Cancers 2018 Oct 31;10(11)
LAG-3 Represents a Marker of CD4+ T Cells with Regulatory Activity in Patients with Bone Fracture.
Wang J, Ti Y, Wang Y, Guo G, Jiang H, Chang M, Qian H, Zhao J, Sun G
Immunological investigations 2018 Jul;47(5):492-503
Immunological investigations 2018 Jul;47(5):492-503
Function and regulation of LAG3 on CD4+CD25- T cells in non-small cell lung cancer.
Ma QY, Huang DY, Zhang HJ, Wang S, Chen XF
Experimental cell research 2017 Nov 15;360(2):358-364
Experimental cell research 2017 Nov 15;360(2):358-364
TIM-3 Engagement Promotes Effector Memory T Cell Differentiation of Human Antigen-Specific CD8 T Cells by Activating mTORC1.
Sabins NC, Chornoguz O, Leander K, Kaplan F, Carter R, Kinder M, Bachman K, Verona R, Shen S, Bhargava V, Santulli-Marotto S
Journal of immunology (Baltimore, Md. : 1950) 2017 Dec 15;199(12):4091-4102
Journal of immunology (Baltimore, Md. : 1950) 2017 Dec 15;199(12):4091-4102
Human lymphocyte activation gene-3 molecules expressed by activated T cells deliver costimulation signal for dendritic cell activation.
Casati C, Camisaschi C, Novellino L, Mazzocchi A, Triebel F, Rivoltini L, Parmiani G, Castelli C
Journal of immunology (Baltimore, Md. : 1950) 2008 Mar 15;180(6):3782-8
Journal of immunology (Baltimore, Md. : 1950) 2008 Mar 15;180(6):3782-8
Human lymphocyte activation gene-3 molecules expressed by activated T cells deliver costimulation signal for dendritic cell activation.
Casati C, Camisaschi C, Novellino L, Mazzocchi A, Triebel F, Rivoltini L, Parmiani G, Castelli C
Journal of immunology (Baltimore, Md. : 1950) 2008 Mar 15;180(6):3782-8
Journal of immunology (Baltimore, Md. : 1950) 2008 Mar 15;180(6):3782-8
A soluble lymphocyte activation gene-3 (sLAG-3) protein as a prognostic factor in human breast cancer expressing estrogen or progesterone receptors.
Triebel F, Hacene K, Pichon MF
Cancer letters 2006 Apr 8;235(1):147-53
Cancer letters 2006 Apr 8;235(1):147-53
The negative regulatory function of the lymphocyte-activation gene-3 co-receptor (CD223) on human T cells.
Maçon-Lemaître L, Triebel F
Immunology 2005 Jun;115(2):170-8
Immunology 2005 Jun;115(2):170-8
Immunological mechanisms elicited at the tumour site by lymphocyte activation gene-3 (LAG-3) versus IL-12: sharing a common Th1 anti-tumour immune pathway.
Di Carlo E, Cappello P, Sorrentino C, D'Antuono T, Pellicciotta A, Giovarelli M, Forni G, Musiani P, Triebel F
The Journal of pathology 2005 Jan;205(1):82-91
The Journal of pathology 2005 Jan;205(1):82-91
T Lymphocytes infiltrating various tumour types express the MHC class II ligand lymphocyte activation gene-3 (LAG-3): role of LAG-3/MHC class II interactions in cell-cell contacts.
Demeure CE, Wolfers J, Martin-Garcia N, Gaulard P, Triebel F
European journal of cancer (Oxford, England : 1990) 2001 Sep;37(13):1709-18
European journal of cancer (Oxford, England : 1990) 2001 Sep;37(13):1709-18
T Lymphocytes infiltrating various tumour types express the MHC class II ligand lymphocyte activation gene-3 (LAG-3): role of LAG-3/MHC class II interactions in cell-cell contacts.
Demeure CE, Wolfers J, Martin-Garcia N, Gaulard P, Triebel F
European journal of cancer (Oxford, England : 1990) 2001 Sep;37(13):1709-18
European journal of cancer (Oxford, England : 1990) 2001 Sep;37(13):1709-18
CD3/TCR complex-associated lymphocyte activation gene-3 molecules inhibit CD3/TCR signaling.
Hannier S, Tournier M, Bismuth G, Triebel F
Journal of immunology (Baltimore, Md. : 1950) 1998 Oct 15;161(8):4058-65
Journal of immunology (Baltimore, Md. : 1950) 1998 Oct 15;161(8):4058-65
Characterization of the major histocompatibility complex class II binding site on LAG-3 protein.
Huard B, Mastrangeli R, Prigent P, Bruniquel D, Donini S, El-Tayar N, Maigret B, Dréano M, Triebel F
Proceedings of the National Academy of Sciences of the United States of America 1997 May 27;94(11):5744-9
Proceedings of the National Academy of Sciences of the United States of America 1997 May 27;94(11):5744-9
Characterization of the major histocompatibility complex class II binding site on LAG-3 protein.
Huard B, Mastrangeli R, Prigent P, Bruniquel D, Donini S, El-Tayar N, Maigret B, Dréano M, Triebel F
Proceedings of the National Academy of Sciences of the United States of America 1997 May 27;94(11):5744-9
Proceedings of the National Academy of Sciences of the United States of America 1997 May 27;94(11):5744-9
Cellular expression and tissue distribution of the human LAG-3-encoded protein, an MHC class II ligand.
Huard B, Gaulard P, Faure F, Hercend T, Triebel F
Immunogenetics 1994;39(3):213-7
Immunogenetics 1994;39(3):213-7
Cellular expression and tissue distribution of the human LAG-3-encoded protein, an MHC class II ligand.
Huard B, Gaulard P, Faure F, Hercend T, Triebel F
Immunogenetics 1994;39(3):213-7
Immunogenetics 1994;39(3):213-7
Characterization of the lymphocyte activation gene 3-encoded protein. A new ligand for human leukocyte antigen class II antigens.
Baixeras E, Huard B, Miossec C, Jitsukawa S, Martin M, Hercend T, Auffray C, Triebel F, Piatier-Tonneau D
The Journal of experimental medicine 1992 Aug 1;176(2):327-37
The Journal of experimental medicine 1992 Aug 1;176(2):327-37
Characterization of the lymphocyte activation gene 3-encoded protein. A new ligand for human leukocyte antigen class II antigens.
Baixeras E, Huard B, Miossec C, Jitsukawa S, Martin M, Hercend T, Auffray C, Triebel F, Piatier-Tonneau D
The Journal of experimental medicine 1992 Aug 1;176(2):327-37
The Journal of experimental medicine 1992 Aug 1;176(2):327-37
No comments: Submit comment
Supportive validation
- Submitted by
- Novus Biologicals (provider)
- Main image
- Experimental details
- Western Blot: LAG-3 Antibody (17B4) [NBP1-97657] - Lane 1: MW marker. Lane 2: LAG-3 (human):Fc (human).
Supportive validation
- Submitted by
- Novus Biologicals (provider)
- Main image
- Experimental details
- Immunohistochemistry-Paraffin: LAG-3 Antibody (17B4) [NBP1-97657] - LAG-3 in human tonsil tissue sample. Image submitted by a verified customer review.
Supportive validation
- Submitted by
- Novus Biologicals (provider)
- Main image
- Experimental details
- Flow Cytometry: LAG-3 Antibody (17B4) [NBP1-97657] - Analysis using the FITC conjugate of NBP1-97657. LAG-3 expression on activated human peripheral blood mononuclear cells (PBMC) detected with LAG-3 (human), mAb (17B4) (FITC).Method: T lymphocytes from human PBMC are stimulated with 1 ug/mL of PHA for three days. Then, after seven days of culture, 3x10^6 three-days PHA-activated human PBMC are treated with LAG-3 (human), mAb (17B4) (FITC) or FITC coupled isotype-matched (IgG1) control MAb (used at a saturating dilution of 1:800 and 1:150 respectively) for 30 min. at 4C in RPMI 1640 and washed twice with 1X PBS. Stained cells are then analysed by FC [4].
- Submitted by
- Novus Biologicals (provider)
- Main image
- Experimental details
- Flow Cytometry: LAG-3 Antibody (17B4) [NBP1-97657] - Analysis using the FITC conjugate of NBP1-97657. Tumor infiltrating lymphocytes (TILs) express LAG-3 (detected using LAG-3 (human), mAb (17B4).
- Submitted by
- Novus Biologicals (provider)
- Main image
- Experimental details
- Flow Cytometry: LAG-3 Antibody (17B4) [NBP1-97657] - Analysis using the FITC conjugate of NBP1-97657. Staining of LAG-3 on CD4+ and CD8+ subpopulations of tumour infiltrating lymphocytes (TILs) detected with LAG-3 (human), mAb (17B4) (FITC).
- Submitted by
- Novus Biologicals (provider)
- Main image
- Experimental details
- Flow Cytometry: LAG-3 Antibody (17B4) [NBP1-97657] - Analysis using the FITC conjugate of NBP1-97657. Method: LAG-3 (human), mAb (17B4) (FITC) (10 ug/mL) (is preincubated with a specific peptide epitope (208b) or a control tetanus toxoid (TT) peptide at different molarities prior to staining of TILs.
- Submitted by
- Novus Biologicals (provider)
- Main image
- Experimental details
- Flow Cytometry: LAG-3 Antibody (17B4) [NBP1-97657] - Analysis using the FITC conjugate of NBP1-97657. LAG-3 staining in resting and PHA activated lymphocytes. Image submitted by a verified customer review.
